Stock ALVO ALVOTECH
Add to a list
To use this feature you must be a member
Log inSign up

All News Alvotech

Equities

ALVO

LU2458332611

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-07-04 pm EDT 		5-day change 1st Jan Change
12.12 USD -0.25% Intraday chart for Alvotech -0.33% +5.57%
Jul. 02 Alvotech Says Study on Proposed Biosimilar to Prolia, Xgeva Meets Primary Endpoints MT
Jul. 02 Alvotech Announces Positive Topline Results from Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva® CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Alvotech : Transactions of Managers and Closely Associated Persons
PU
Alvotech : Major shareholding notifications Major Holdings Notification (Annex A) ATP Holdings ehf (20240702)
PU
Alvotech Says Study on Proposed Biosimilar to Prolia, Xgeva Meets Primary Endpoints
MT
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
GL
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®
CI
Alvotech Issues New Shares to Holders of Convertible Bonds
GL
Alvotech Reports Preliminary Q2 Revenue; Shares Rise Pre-Bell
MT
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
GL
Alvotech : Text of Request Filed With the U.S. Securities and Exchange Commission
PU
Alvotech : Transactions of Managers and Closely Associated Persons
PU
Nordic Stocks Decrease Wednesday; Alvotech Falls Furthest
DJ
Alvotech Expects to Issue Up to 22 Million Shares Following Bond Conversion
MT
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
GL
Alvotech : Managers' transactions Alvotech Managers' Transaction Notification Richard Davies (Arendt 20240625)
PU
Alvotech and ADVANZ PHARMA Sign Commercialization Agreement for Proposed Biosimilar to Eylea LD/HD in Europe
AQ
Alvotech, Advanz Pharma Collaborate to Supply, Commercialize Proposed Biosimilar to Eylea in Europe
MT
Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma
MT
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
GL
Annual General Meeting of Shareholders of the Company held on 7 June 2024 at 9:00 a.m. CEST at 41A, Avenue John F. Kennedy, L 1855 Luxembourg, Grand Duchy of Luxembourg Form 6 K
PU
Alvotech Appoints Hjörleifur Pálsson as Director
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALVO Stock
  4. News Alvotech